Immuron Limited (IMRN)
Immuron Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Immuron Limited (IMRN) is a Biotechnology company based in AU with a market capitalization of $7.2M. Revenue grew 48.6% year-over-year and free cash flow was negative at -$4.3M. This page tracks IMRN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
AU · 7 employees · IPO Jun 9, 2017
Valuation
Valuation & price
$1.00as of May 26, 2026· -57.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$7.2M
Market cap
48.6%
Revenue growth (YoY)
65.4%
Gross margin
-$4.3M
Free cash flow (USD)
-$5.7M
Net debt
Net cash position
1.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed Jul 15, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 20, 2026Filing
Investor Presentation
- 6-K filingJul 20, 2026Filing
Investor Presentation
- Annual reportJul 15, 2026Filing
Annual Report Filed
- 6-K filingJul 6, 2026Filing
Partnering Update
- 6-K filingJun 29, 2026Filing
Notification of Cessation of Securities
- 6-K filingJun 23, 2026Filing
Unmarketable Parcel Facility Update
- 6-K filingJun 22, 2026Filing
Notification of Cessation of Securities
- 6-K filingMay 28, 2026Filing
Response to ASX Price Query
- 6-K filingMay 8, 2026Filing
Emerging Growth Conference Presentation
- 6-K filingApr 30, 2026Filing
Emerging Growth Conference Presentation
Questions
Frequently asked questions
What is Immuron Limited's market cap?
Immuron Limited (IMRN) has a market capitalization of $7.2M.
What is IMRN's P/E ratio?
A meaningful P/E ratio is not available for IMRN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying IMRN stock?
SEC Form 4 filings show no open-market insider buys at Immuron Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.